2024 Rome, Italy

II-19 Rolien Bosch
Linking 4GI Glucose Homeostasis and Hall Body Composition Models to study GLP-1R Agonist effects on glucose and body weight
Wednesday 15:35-17:00
II-43 Marwa Elhefnawy
Quantifying the rate of blood glucose changes over the acute stage of ischemic stroke among patients with diabetes.
Wednesday 15:35-17:00
II-45 Edoardo Faggionato
Assessing insulin sensitivity, glucose effectiveness, and β-cell responsivity using an integrated glucose, insulin, and C-peptide minimal model
Wednesday 15:35-17:00
II-56 Benjamin Guiastrennec
Model-Based Translational Rapamycin Dose Selection to Promote Engraftment and Expansion of the Engineered Regulatory T cell (EngTreg) product GNTI-122 in Human
Wednesday 15:35-17:00
II-79 Hanna Kunina
Blood glucose profile evaluation with model-based approach using continuous glucose monitoring data
Wednesday 15:35-17:00
II-83 Rune Overgaard
Similar efficacy and gastrointestinal tolerability versus exposure for oral and subcutaneous semaglutide
Wednesday 15:35-17:00
II-89 Nelleke Snelder
From glomerular filtration rate to renal composite endpoint: an integrated time-to-event analysis of finerenone in phase 3 studies.
Wednesday 15:35-17:00
II-91 Britta Steffens
Enhanced pharmacometrics model utilizes heart rate to monitor thyroid function in pediatric Gravesí disease under pharmacotherapy
Wednesday 15:35-17:00